Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini filed Amendment No. 8 to their Schedule 13D on Royalty Pharma plc, updating their ownership and corporate details. As of June 12, 2026, they may be deemed to beneficially own 21,366,927 Class A shares, representing 4.8% of the outstanding class based on 443,274,104 shares. The amendment notes that they are no longer deemed beneficial owners of more than five percent of Royalty Pharma’s Class A shares and states this is their final amendment and exit filing. The filing also records the trust and fund structure through which the shares are held and disclaims beneficial ownership by various board members and beneficiaries.
Royalty Pharma plc director Elizabeth H. Weatherman received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The grant was made at no cash cost to her and is classified as a compensation-related acquisition, not an open-market purchase.
The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award agreement. After this grant, she holds 13,103 shares directly.
Norden Gregory reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Gregory Norden received a new equity grant. On June 5, 2026, he was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units at a price of $0.00 per share under the company’s 2020 Independent Director Equity Incentive Plan.
The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholders’ meeting, subject to plan and award terms. Following this grant, Norden directly holds 196,348 Class A Ordinary Shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the company’s 2020 Independent Director Equity Incentive Plan. These units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholder meeting, subject to plan and award terms. Following this grant, Love directly holds 58,393 Class A Ordinary Shares.
Royalty Pharma plc director David C. Hodgson reported an acquisition of 4,545 restricted stock units linked to Class A ordinary shares as equity compensation. The award was granted under the company’s 2020 Independent Director Equity Incentive Plan and is scheduled to vest 100% on the earlier of one year from grant or the next annual shareholder meeting. The restricted stock units are held solely for the benefit of General Atlantic Service Company, L.P., and Hodgson disclaims beneficial ownership of the underlying shares. Following this grant, 37,873 Class A ordinary shares are reported as directly held.
Ho Carole reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Carole Ho reported a grant of 4,545 Class A Ordinary Shares in the form of restricted stock units. The award was made at a price of $0.00 per share as compensation and is scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award terms. Following this grant, Ho holds 4,545 shares directly and 8,558 shares indirectly through the Rohatgi-Ho Family 2009 Revocable Trust, where she serves as trustee.
Engelbert Catherine M. reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Catherine M. Engelbert received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The award was granted at no cash cost to her and was made under the company’s 2020 Independent Director Equity Incentive Plan.
The restricted stock units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of shareholders, subject to plan and award terms. Following this grant, Engelbert directly holds 55,673 Class A Ordinary Shares.
Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Vlad Coric received an equity award of 4,545 Class A Ordinary Shares at no cost, reported as a grant under the company’s 2020 Independent Director Equity Incentive Plan. The award consists of restricted stock units scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the plan and award terms. Following this grant, Coric directly holds 15,343 Class A Ordinary Shares.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. These units were granted at no cash cost and increase her directly held position to 78,492 shares.
The award was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan and is generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to plan and award terms. This is a routine, compensation-related grant rather than an open-market share purchase or sale.
Royalty Pharma plc reported the voting results from its 2026 Annual General Meeting of Shareholders. Shareholders representing 508,180,103 Class A and Class B shares, or 88.08% of eligible voting power, were present or represented, providing a strong quorum.
All nine director nominees were elected to serve until the 2027 annual meeting. Shareholders approved, on a non-binding advisory basis, compensation for named executive officers and the U.K. directors’ remuneration report. They also ratified Ernst & Young LLP as independent registered public accounting firm and re-appointed Ernst & Young as U.K. statutory auditor.
Shareholders authorized the board to determine the U.K. auditor’s remuneration, approve terms for potential repurchases of Class A ordinary shares, and grant the board authority to allot shares, including authority to allot shares without rights of pre-emption.